Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Clearwater, Florida


Purpose:

The purpose of this trial is to evaluate the safety and indicators of efficacy of up to 4 doses of orally administered dabigatran etexilate, administered twice daily, compared to placebo when given in addition to dual antiplatelet treatment in patients with an index event (MI) at high risk for new ischaemic cardiovascular events.


Criteria:

Inclusion criteria Patients with acute coronary syndromes with at least one additional risk factor for cardiovascular complications. Exclusion criteria 1. Long term treatment with any other oral anticoagulant 2. Severe/disabling stroke within last 6 months 3. Conditions associated with increased bleeding risk 4. Anaemia or thrombocytopenia 5. Severe renal impairment 6. Liver disease 7. Positive pregnancy test


NCT ID:

NCT00621855


Primary Contact:

Study Chair
Boehringer Ingelheim
Boehringer Ingelheim Pharmaceuticals


Backup Contact:

N/A


Location Contact:

Clearwater, Florida
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: January 17, 2018

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.